Get started
CRISPR THERAPEUTICS AGCRISPR THERAPEUTICS AGCRISPR THERAPEUTICS AG

CRISPR THERAPEUTICS AG

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

CRSP/N trade ideas

Cup and Handle Patterns above PatternsAnother cup and handle has formed above the old cup and handle If you enjoy volatility this is a good one for you. This one may pull back again close to handle low of new cup and handle Remains to be seen Be patient and pick a good entry that works for you Stop to your tolerance or below handle low The last time this one reached long entry, iit did not hold on to the high. Deep pull back ensued and now CRSP seems to have energy again I see now a new all time high was just made but has pulled back again. If you like this stock, beware of volatility It appears Gene editing companies are hot as of late/TXG is another NV is high and short interest is mediocre but a bit higher than I like Be safe and be patient (o: Not a recommendation CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. It develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, the company is developing allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. Further, it engages in developing regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, Duchenne muscular dystrophy, and cystic fibrosis. The company has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.
NASDAQ:CRSPLong
by lauralea
Ascending Triangle & Triple Bottom for CRSP?Notice the dark blue pattern on the chart, there's noticeably a Ascending Triangle and coincidentally a bullish inverted H&S where I have placed the green lines. Above each green line is appears to be a bottom, and there's three very noticeable on the line chart as opposed to the hollow candle chart. I have placed three blue finger icons so there is no confusion, each finger represents a bottom of the Triple Bottom. On the RSI there's was clearly a modest divergence, if the Ascending Triangle breakout to the upside the RSI is going to need to create a higher high and break out of the pattern to the upside negating the possibility of this ending in a bearish divergence & descending triangle.
NASDAQ:CRSPLong
by ScotianBot
$CRSP Consolidation Channel Long Right Now$CRSP has formed a perfect consolidation channel between $86 & $97. The daily squeeze momentum is turning positive after this 6 week consolidation and looks ready to make a move to new highs, potentially above $100 to $120. Long $CRSP and other gene editing stocks like $EDIT $TWST $NVTA $NTLA $CLLS which have very similar setups/positive momentum. Buy the 9/18 $100 calls for around $5 and stand to make out nicely on a breakout move above $100.
NASDAQ:CRSPLong
by UnknownUnicorn7308096
CRISPR - Long Term OutlookCrispr is still on the rise and trading within it's rising channel. It looks like it has completed a 5th wave and is due for a correction. There is major support around $73.00 which is also the 61.8% fib level. This may present a nice buying opportunity if it drops to around $73.00 and that support holds up. I think gene editing and genetic engineering will continue to have positive momentum until at least November. Disclaimer: This is not financial advice. Do your own research and due diligence. Good Luck!
NASDAQ:CRSP
by ChrisPtaco_32
1